4.6 Article

Association Between Use of Anti-gout Preparations and Dementia: Nested Case-Control Nationwide Population-Based Cohort Study

期刊

FRONTIERS IN MEDICINE
卷 7, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2020.607808

关键词

gout; uric acid; dementia; benzbromarone; elderly

资金

  1. Taichung Armed Forces General Hospital [107A09]
  2. Department of Medical Education and Research, Taichung Armed Forces General Hospital

向作者/读者索取更多资源

Long-term use of benzbromarone may reduce the risk of dementia in gout patients, especially with a more pronounced effect in males. Further prospective trials are needed to confirm these findings.
Objectives: Gout is the most common form of inflammatory arthritis and was found to be independently associated with incident dementia in the elderly. However, the associations between anti-gout preparations and dementia were not well-studied. Methods: Data were collected from Taiwan's National Health Insurance Research Database (NHIRD). A 2005-2013 retrospective cohort study was conducted, and all investigated subjects were identified by International Statistical Classification of Diseases and Related Health Problems, 9th Revision, Clinical Modification. Conditional logistic regression was used to evaluate the odds ratio of dementia in relation to different gout preparations (benzbromarone, allopurinol, sulfinpyrazone, probenecid) and number of days of anti-gout preparation use, after adjustment for potential confounding variables. Results: A total of 3,242 gout patients with and without dementia were selected from the NHIRD and included in the final analysis after 1:1 matching for age, gender, and diagnosis year of gout. In the anti-gout preparations, only use of Benzbromarone decreased the risk of dementia (adjusted OR, 0.81; 95% CI, 0.68-0.97). The result of the subgroup analysis revealed a trend toward a lower risk of dementia with longer use of benzbromarone. Use of benzbromarone for >= 180 days showed a significantly lower risk of dementia (adjusted OR, 0.72; 95% CI, 0.58-0.89). Moreover, the protective effect was more pronounced in males compared with females. Conclusion: This cohort study reveals that gout patients taking benzbromarone are at a decreased risk of developing incident dementia, especially with longer use and in male. Further prospective trials are warranted to confirm our findings.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据